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preponderance of locally advanced tumors, local control and 
overall survival are encouraging. 
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Purpose/Objective: To asses the clinical utility of 18F-FDG 
PET-CT in patients with advanced head and neck squamous 
cell carcinoma (HNSCC), considering the prognostic value in 
staging study and the response to radiotherapy (RT) 
treatment with or without chemotherapy.  
Materials and Methods: Radiotherapy planning was 
performed with 18F-FDG PET-CT in 28 patients (p) diagnosed 
of HNSCC between august 2009 and august 2013. 
Male/Female: 23/5. Mean age: 60 years (range: 49-74). 
Location primary tumor: larynx 11 (39%), oropharynx 6 (21%), 
hypopharynx 6 (21%) and oral cavity 5 (18%). Clinical tumor 
stage: III 4 (14%); IVa 23 (82%); IVb: 1 (4%). They were 
treated at our Center with curative intent using RT (mean 
dosis 6943 cGy, range 6600-7000): with or without 
chemotherapy (concurrent n=25 and induction n=14). 
Minimum follow-up 12 months. Response was assessed by 
18F-FDG PET-CT at least 8 weeks after completion of 
radiotherapy (mean 15 weeks, range 8-45). Maximum 
standard uptake value (SUVmax) of primary tumor (T) and 
lymph nodes (N) in staging PET were measured and compared 
in both groups of patients: those with complete response at 
treatment (CR) and those with no complete response (noCR). 
Sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy (Acc) were 
calculated in the response 18F-FDG PET-CT.  
Results: Basal PET mean SUVmax for T and N was 19,48 and 
10.50 respectively. The response 18F-FDG PET-CT showed 
complete metabolic response in 19 p (68%), partial response 
in 5 p (18%) and progression disease in 4 p (14%), with 
evidence of nodal disease in 4 p (14%) (mean SUVmax 4,89) 
and residual tumor in 8 p (29%) (mean SUVmax 8,34). In the 
follow-up period 17 p had no recurrence. Sensitivity, 
specificity, PPV, NPV and Acc of response PET-CT was 88%, 
95%, 88%, 95% and 93% for primary tumor, and 67%, 91%, 50%, 
95% and 88% for nodal disease. Overall survival (OS) and 
disease-free survival (DFS) at 2 years were 79% and 64%, 
respectively. Mean SUVmax of T in CR group and noCR were 
19,33 and 19,68 respectively. Mean SUVmax of N were 9,31 
and 12,41 respectively. We did not find differences 
statistically significant between nodal or primary tumor 
SUVmax and overall survival (p=0,9173 for T, p=0,3165 for N).  
Conclusions: 18F-FDG PET-CT is a useful method for assessing 
response after radical chemoradiotherapy in advanced 
HNSCC, showing a high negative predictive value for primary 
tumor and lymph nodes. In our cohort, higher primary tumor 
and nodal SUVmax was not associated with lower rates of 
survival. Multi-institutional trials are required to establish 
stronger conclusion on this matter. 
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Purpose/Objective: To report initial results of a prospective 
clinical trial aimed to assess instrumental swallowing function 
in nasopharynx and oropharynx cancers after radio or 
chemoradiotherapy using intensity-modulated radiotherapy 
(IMRT). 
Materials and Methods: IMRT was delivered aiming to spare 
the swallowing organ at risk (SWOARs) for Stage II-IV naso and 
oropharynx cancer. Objective instrumental assessment 
included Videofluoroscopy (VFS), Fiberoptic Endoscopic 
Evaluation of Swallowing (FEES) and Oro-Pharyngeal-
Esophageal Scintigraphy (OPES) at baseline and 1,6 and 12 
months after radiotherapy. Dysphagia parameters scores 
were calculated and reported at each exam both after liquid 
(L) and semi-liquid (SL) bolus intake: pre-swallowing 
penetration, aspiration, pharyngeal transit time (PTT) and 
hypopharyngeal retention index (HPRI) 
Results: Overall 20 patients (6 Nasophaynx and 14 
Oropharynx) completed treatment and instrumental 
assessment at 1 month. Correlations between the pre and 
post-treatment changes in HPRI scores resulted statistically 
significant both at FEES-L (p=0,021) and SL (p=0,02) and at 
VFS-L (p=0,008) and SL (p=0,005). Moreover significant 
relationships between baseline and 1 month HPRI score at 
FEES-L and FEES-SL (p=0,005) as well as at VFS-L and VFS-SL 
(p<0,001), were observed. Differently, PTT resulted not 
significantly affected by radiotherapy (p>0,2). Only few 
patients experienced pre-swallowing penetration (1 patient 
with base of tongue cancer at FEES-L and SL) and aspiration 
(1 patient with nasopharynx cancer at OPES-L and FEES-SL) 
after radiotherapy 
Conclusions: Our early results showed that radiotherapy 
significantly increased the post-swallowing HPRI. Longer 
follow-up will be necessary to evaluate if the increase of 
HPRI is related to an high risk to develop late aspiration. 
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Purpose/Objective: It was previously shown that SUVmax of 
pretreatment 18-Fluordesoxyglucose PET/CT (FDG-PET) of 
the primary in locally advanced lung cancer patients was 
associated with higher risk of distant failure (DF) (V.J. Nair et 
al., 2014). The following analysis tries to find similarities in 
case of locally advanced, non-metastatic patients with 
